iTeos Reports Topline Interim Results from GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients

Core Insights - iTeos Therapeutics and GSK have decided to terminate the belrestotug development program due to the failure to meet established criteria for clinically meaningful improvements in progression-free survival in the GALAXIES Lung-201 trial [1][3] - The GALAXIES Lung-201 trial showed clinically meaningful improvements in the primary endpoint of objective response rate (ORR), but did not meet criteria for the secondary endpoint of progression-free survival [2][3] - iTeos is initiating a targeted review of strategic alternatives to maximize shareholder value following the termination of the belrestotug program [3][4] Company Overview - iTeos Therapeutics is a clinical-stage biopharmaceutical company focused on developing immuno-oncology therapeutics [5] - The company is headquartered in Watertown, MA, with a research center in Gosselies, Belgium [5] Product Information - Belrestotug is a monoclonal antibody targeting TIGIT, designed to enhance the antitumor response through immune modulation [6]